Monte Rosa (GLUE) news
Recent news
Monte Rosa Therapeutics - to provide Phase 1/2 study update on MRT-2359 plus enzalutamide by year-end
AInvest Wire · 7d agoMonte Rosa Therapeutics Inc: Wedbush cuts target price to $27 from $37
AInvest Wire · Aug 3, 2026Monte Rosa shares tumble 44% in premarket trading
Monte Rosa Therapeutics, Inc. (GLUE) shares have declined sharply in premarket trading, falling 44% to $4.58 as of July 31, 2026. This represents a significant reversal from earlier gains following a collaboration agreement with Novartis, which had driven the stock up 65.3% to $7.94 in premarket…
AInvest Wire · Jul 31, 2026Jefferies raises target price to $40 from $30 for Montage Rosa Therapeutics Inc
Jefferies & Co. has raised its price target for Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) to $22.00 from $18.00, while maintaining a Buy rating, citing positive clinical data for MRT-2359 . The stock has surged 308% over the past six months and is currently near its 52-week high . The firm…
AInvest Wire · Jul 27, 2026ImportantMonte Rosa jumps 30% on $150M license deal with Novartis
Monte Rosa jumps 30% on $150M license deal with Novartis Monte Rosa Therapeutics (Nasdaq: GLUE) shares surged by more than 30% following the announcement of a strategic collaboration and licensing agreement with global healthcare leader Roche [1]. This collaboration aims to discover and develop…
AInvest Wire · Oct 28, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.